Addition of Dydrogesterone to the Luteal Phase Support After Fresh Embryo Transfer

NCT04408144 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2021-10-04

No results posted yet for this study

Summary

Randomized controlled study, open label to compare effectiveness of addition of dydrogesterone 20mg to the standard luteal phase support treatment after fresh embryos transfer.

Conditions

Interventions

DRUG

Dydrogesterone 10mg Oral Tablet

oral 10mg dydrogesterone (Duphaston) 2 times daily

Sponsors & Collaborators

  • Laniado Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2022-05-31
Completion
2023-05-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04408144 on ClinicalTrials.gov